GlassScriptPhysician profile
Albert H Quan
NPI 1689615114
$5,547.02
in general payments reported to CMS, 2019-2025
11 companies · $99.80 in 2025
The $99.80 reported for 2025 was less than what a typical Pediatric Nephrology provider received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.73 · 2021: $5,183 · 2022: $20.79 · 2023: $103 · 2024: $111 · 2025: $99.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $313.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $5,115.00 | 2021 | |
| Travere Therapeutics, INC. | $103.70 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $60.88 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $50.67 | 2025 | Ultomiris |
| One Lambda, INC. | $48.63 | 2021 | |
| Novo Nordisk INC | $45.86 | 2024 | Rivfloza |
| Aurinia Pharma U.S., INC. | $39.38 | 2021-2022 | |
| Kyowa Kirin, INC. | $23.69 | 2024 | Crysvita |
| Merck Sharp & Dohme LLC | $22.33 | 2025 | Prevymis |
| Ani Pharmaceuticals, INC. | $19.15 | 2024 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $17.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Quan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.